Infinium Pharmachem Ltd
Infinium Pharmachem Q2 FY26: Revenue ₹84.05 Cr, EBITDA margin 13.46%
Q2 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Infinium Pharmachem Ltd's Q2 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). EBITDA for H1FY26: Rs 11.44 crore, up 20% YoY from Rs 9.55 crore in H1FY25 - EBITDA Margin (operating margin) for H1FY26: 13.46%, improved by 210 bps from 11.36% in H1FY25 - Profit After Tax (PAT)
From Infinium Pharmachem Ltd's Q2 FY26 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22).
- EBITDA for H1FY26: Rs 11.44 crore, up 20% YoY (Page 22).
- PAT for H1FY26: Rs 6.52 crore, up 34.98% YoY (Page 22).
- Full year FY25 Revenue: Rs 155.71 crore, up 14.78% from Rs 135.66 crore in FY24 (Page 22).
- Outlook states target topline of Rs 200 crore by FY26 with a sustainable 20% YoY growth rate (Page 12).
2 more points from Infinium Pharmachem Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Infinium Pharmachem Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Contrast Media Project: Nearing completion; expected conclusion by December 2025. Peak revenue anticipated at Rs 100 Cr from FY 2026-27. Pilot scale commenced for Atipa and Atipa Dichloride; commercial samples offered. Discussions ongoing for long-term supply contracts.
- Iodine Extraction Project (JV in Texas): Commercial production expected by December 2026. Land secured for future scale-up supporting API/intermediate growth. The process is patented (4 US patents granted, 8 under review) improving prilled medical-grade iodine yield to 99.5% purity.
- Capacity Utilization: Currently at ~20% capacity utilization (FY24), with plans to improve via increased captive iodine consumption, supporting high ROCE.
2 more points from Infinium Pharmachem Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Fundraising & Capital Structure
See what Infinium Pharmachem Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Infinium Pharmachem Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Continue your research
What Infinium Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
- Emcure Pharmaceuticals Ltd (Q2 FY26)
Emcure Pharmaceuticals delivered a strong Q2 FY26 with 25% PAT growth, reporting highest quarterly profit of INR 251 crores. Key concall takeaways from Emcure…
Arthneeti Pro · Annual
Infinium Pharmachem Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Infinium Pharmachem Ltd Q2 FY26 results?
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). EBITDA for H1FY26: Rs 11.44 crore, up 20% YoY from Rs 9.55 crore in H1FY25 - EBITDA Margin (operating margin) for H1FY26: 13.46%, improved by 210 bps from 11.36% in H1FY25 - Profit After Tax (PAT)
What is Infinium Pharmachem Ltd share price analysis?
Infinium Pharmachem Ltd currently shows a neutral. The stock trades at a P/E of 39.1 with a market cap of ₹475 Cr. Investors should review the full earnings analysis for detailed insights.
Is Infinium Pharmachem Ltd planning capital expenditure?
Contrast Media Project: Nearing completion; expected conclusion by December 2025.
Keep Infinium Pharmachem Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.